Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Hypertension. 2020 Nov 2;76(6):1744–1752. doi: 10.1161/HYPERTENSIONAHA.120.15435

Figure 5: Intrarenal administration of miR-133a inhibits HS-induced increases in blood pressure subsequent to knockdown of TNF in the kidney.

Figure 5:

A) Daily blood pressure measurements for mice implanted with radiotelemetry probes, injected with either U6-TNF-ex4 (~5 × 107 TU) or a combination of U6-TNF-ex4 and miR-133a (~2 × 108 TU) into both kidneys, and given HS for 7 days. B) Summation of MAP for mice given HS for 7 days. C) AGT mRNA expression was determined after intrarenal injection of either U6-TNF-ex4 or a combination of U6-TNF-ex4 and miR-133a in mice given HS for 7 days. D) miR-133a expression in liver was measured in mice given NS (−) or HS for 7 days. E): AGT mRNA expression in liver was measured following intrarenal injection of either U6-TNF-ex4 or a combination of U6-TNF-ex4 and miR-133a in mice given HS for 7 days. Data are shown as mean ± SE; (n=10, ANOVA and t test).